$TECX News
Last published 2d ago
- 2d agoTECXTectonic Therapeutic to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic
- 6d agoTECXTectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireReported favorable safety, tolerability and pharmacokinetic ("PK") results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adult volunteers; FDA granted TX2100 Fast Track
- 2mo agoTECXTectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic
- 3mo agoTECXTectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireEnrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction ("PH-HFpEF") with topline results anticipated in
- 5mo agoTECXTectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF PatientsGlobeNewswireAPEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF)APEX Phase 2 trial enrolled 191
- 6mo agoTECXTectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireTX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027TX2100 advanced into Phase 1a healthy volunteer clinical trial in February 2026 as a
- 6mo agoTECXTectonic Therapeutic Appoints Jessica Chutter to Board of DirectorsGlobeNewswireWATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 8mo agoTECXTectonic Therapeutic to Participate in March Investor ConferencesGlobeNewswireWATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 8mo agoTECXTectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewswireAnnounced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF") in October 2025. Topline
- 8mo agoMRNATECXTectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the BoardGlobeNewswireWATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 9mo agoTECXTectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026GlobeNewswireWATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 11mo agoTECXTectonic Therapeutic to Participate in December Investor ConferencesGlobeNewswireWATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 1y agoTECXTectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswirePositive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced
- 1y agoTECXTectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEFGlobeNewswireTX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH‑HFrEF")TX45 was well tolerated in patients with
- 1y agoTECXTectonic Therapeutic to Participate in September Investor ConferencesGlobeNewswireWATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 1y agoTECXTectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireTX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45's safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ("PH-ILD", Group 3 PH)
- 1y agoTECXTectonic Therapeutic Joins Russell 3000® IndexGlobeNewswireWATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 1y agoTECXTectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025GlobeNewswireData confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction
- 1y agoTECXTectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswireInterim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with
- 1y agoTECXTectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care ConferenceGlobeNewswireWATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 1y agoTECXTectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025GlobeNewswireWATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 1y agoTECXTectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsGlobeNewswireTX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved
- 1y agoTECXTectonic Therapeutic to Participate in March Investor ConferencesGlobeNewswireWATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 1y agoTECXTectonic Announces $185 Million Private PlacementGlobeNewswireWATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), today announced that it has entered into a securities purchase agreement for a private investment in public
- 1y agoTECXTectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEFGlobeNewswireTX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient
- 1y agoTECXTectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024GlobeNewswireWATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic") a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 1y agoTECXTectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 2y agoTECXTectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion ProteinGlobeNewswirePhase 1a results support further development of TX000045 ("TX45") for Group 2 Pulmonary Hypertension in HFpEF ("PH-HFpEF"), based on favorable pharmacokinetic profile and impact on renal plasma flow ("RPF")TX45 showed a
- 2y agoTECXTectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswirePatient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical
- 2y agoTECXTectonic Therapeutic to Present Phase 1a Data at AHA 2024GlobeNewswireWATERTOWN, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 2y agoTECXTectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45GlobeNewswireTX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at the American Heart
- 2y agoTECXTectonic Therapeutic to Participate in September Investor ConferencesGlobeNewswireWATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and
- 2y agoTECXTectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswireTX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in
- 2y agoTECXTectonic Therapeutic Announces US IND Clearance for Lead Program, TX45GlobeNewswireTX45 is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF), a serious condition estimated to affect over
- 2y agoTECXTectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 MillionBusiness WireTectonic will be focused on advancing a pipeline of novel G-protein-coupled receptor ("GPCR") targeted biologic therapies, including the lead program, TX45, a Fc-relaxin fusion TX45 is currently being evaluated in